MEDGm Scrutinized Over GLP-1 Pricing and Treatment Paths

MEDGm, a telehealth weight-management platform, has faced scrutiny over its pricing and service details following an advertising campaign that promoted a starting price of $169 per month for its compounded GLP-1 medication. The review, conducted by MEDGm, explores the true costs and treatment options available to consumers.

The platform connects adults aged 18 and older with independent, U.S.-licensed medical providers for compounded GLP-1 medication, which includes semaglutide and tirzepatide. MEDGm does not itself prescribe medication; instead, it facilitates access to these compounded drugs and branded products such as Ozempic, Wegovy, and Zepbound. According to the company, the assessment for eligibility is conducted by a licensed healthcare provider, who may also recommend a different formulation or dosage based on the individual's needs.

The starting price of $169 per month includes access to either a compounded GLP-1 injection or tablet, or a membership tier for brand-name medications such as Zepbound, Wegovy, and Ozempic. The compounded GLP-1 injection starts at $169 per month, while the compounded GLP-1 tablet begins at $239 per month. For brand-name medications, the cost breaks down into a $99 membership fee plus the cost of the medication.

Consumers interested in MEDGm's services should be aware that the provider group, OpenLoop Healthcare Partners, PC, and its affiliated entities, handle the clinical services, diagnoses, and treatments. The consent forms explicitly state that these providers are responsible for clinical care, not MEDGm itself. MEDGm's role is limited to facilitating access to the platform and the providers.

Safety information is a critical aspect of the treatment, as the GLP-1 drug class can cause various side effects, including nausea, vomiting, diarrhea, and constipation, as well as more serious conditions such as dehydration, hypoglycemia, gallbladder disease, and pancreatitis. The FDA's boxed warning for medullary thyroid carcinoma is also disclosed, though the specific products carrying this warning are not identified.

MEDGm's terms and conditions state that compounded medications may differ in appearance, color, viscosity, packaging, concentration, excipients, and administration instructions from the FDA-approved brand-name versions. These compounded products are not therapeutically equivalent to, and are not substitutes for, FDA-approved products.

The platform offers four distinct paths to GLP-1 medication: compounded GLP-1 injections, compounded GLP-1 tablets, Zepbound injections, and Wegovy or Ozempic pills. The brand notes that availability is subject to change for all three brand-name paths, and off-label use is a legally permitted and common medical practice. Providers have the discretion to recommend different formulations or dosages based on clinical judgment.

Consumers should also be aware that the $99 and $171 membership tiers for brand-name products are separate from the medication cost itself. MEDGm's pricing page does not show an all-in total for these paths, only the membership fee plus the medication cost.

In conclusion, consumers interested in MEDGm's services should carefully review the details provided by the platform and consider their individual needs and preferences. It is recommended to discuss any concerns with a healthcare provider to ensure the best treatment path is chosen.